Quality specifications for biochemical markers of myocardial injury

被引:19
|
作者
Zaninotto, M [1 ]
Mion, M [1 ]
Altinier, S [1 ]
Forni, M [1 ]
Plebani, M [1 ]
机构
[1] UNiv Hosp Padova, Azienda Osped Padova, Dept Lab Med, I-35128 Padua, Italy
关键词
troponin I; troponin T; acute coronary syndrome; heterophilic antibodies; macrocomplex;
D O I
10.1016/j.cccn.2004.02.035
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: The current approach to the diagnosis and monitoring of myocardial damage, recognizes to biochemical markers, and in particular to troponins, a key role being well demonstrated that all elevated values were associated with a worsened prognosis. In 2001, the IFCC Committee on Standardization of Markers of Cardiac Damage published guidelines addressing the quality specifications for troponin assays in order to guarantee an analytical performance satisfying medical requirements and to standardize the quality of commercial methods. We describe how the application of quality specifications may be useful in daily practice, in order to provide advice to clinicians in the investigations of complex clinical cases of patients suffering from myocardial damage. Materials and methods: The samples from three patients (cases 1-3) admitted to the hospital with symptoms suggestive of cardiac disease, showing high troponin I (cTnI) values not correlated with clinical condition, were investigated in order to verify the accuracy of the laboratory data. The standard of quality specifications related to assay specificity, imprecision and interferences were evaluated using different platforms for cTnI assays, carrying out imprecision profile and specific studies on more common interferents in immunoassays. Results: The obtained results allow us to demonstrate two cases of false-positive cTnI values attributable to a macrocomplex between a modified "in vivo" cTnI and immunoglobulin G (case 1) and to a presence of heterophilic antibodies affecting the RxL Dimension procedure (case 3). Instead, the accuracy of data obtained in case 2 was evidenced by the imprecision profile obtained in our laboratory and by the comparison of results between different laboratories using same platform. Conclusions: The lack of standardization as well as the wide differences in the development of each assay give rise to major concerns regarding cTnI determinations. The laboratory must therefore check the compliance between the analytical characteristics of the method utilised against recommended quality specifications for a reliable understanding of the frequency of false-positive results as well as other serious analytical errors. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:65 / 72
页数:8
相关论文
共 50 条
  • [21] Markers of myocardial injury in the prediction of short-term COVID-19 prognosis
    Calvo-Fernandez, Alicia
    Izquierdo, Andrea
    Subirana, Isaac
    Farre, Nuria
    Vila, Joan
    Duran, Xavier
    Garcia-Guimaraes, Marcos
    Valdivielso, Sandra
    Cabero, Paula
    Soler, Cristina
    Garcia-Ribas, Cora
    Rodriguez, Clara
    Llagostera, Marc
    Mojon, Diana
    Vicente, Miren
    Sole-Gonzalez, Eduard
    Sanchez-Carpintero, Andrea
    Tevar, Cristina
    Marrugat, Jaume
    Vaquerizo, Beatriz
    REVISTA ESPANOLA DE CARDIOLOGIA, 2021, 74 (07): : 576 - 583
  • [22] Changes of monocyte subsets in patients with acute coronary syndrome and correlation with myocardial injury markers
    Zhu, Li
    Yin, Yigang
    Zhou, Ruifang
    Lin, Jie
    Li, Jianming
    Ye, Jun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (06): : 7266 - 7271
  • [23] Biochemical markers of muscular damage
    Brancaccio, Paola
    Lippi, Giuseppe
    Maffulli, Nicola
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2010, 48 (06) : 757 - 767
  • [24] Suppression of Myocardial Injury Markers following Percutaneous Coronary Interventions by Pre-treatment with Carvedilol
    Moloudi, Abdolrasoul
    Sabzi, Feridoun
    Rashidi, Shirin
    INTERNATIONAL CARDIOVASCULAR RESEARCH JOURNAL, 2012, 6 (03) : 88 - 91
  • [25] The use of biochemical markers in ischaemic heart disease: summary of the roundtable and extrapolations
    Henderson, AR
    Gerhardt, W
    Apple, FS
    CLINICA CHIMICA ACTA, 1998, 272 (01) : 93 - 100
  • [26] Biochemical markers in acute coronary syndrome
    Ramasamy, I.
    CLINICA CHIMICA ACTA, 2011, 412 (15-16) : 1279 - 1296
  • [27] Pregnancy-associated plasma protein A and procalcitonin as markers of myocardial injury in patients with acute coronary syndrome
    Bayir, Aysegul
    Kara, Hasan
    Kiyici, Aysel
    Ozturk, Bahadir
    Sivrikaya, Abdullah
    Akyurek, Fikret
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2015, 45 (01) : 159 - 163
  • [28] Investigation of the relationship between serum homocysteine levels and cardiac markers and biochemical parameters in ST- elevated myocardial infarction
    Taskin, Ergin
    Karapehlivan, Mahmut
    EUROPEAN JOURNAL OF ANATOMY, 2025, 29 (02) : 205 - 214
  • [29] Biomarkers of myocardial injury
    Rodriguez Blanco, Suilbert
    Almeida Gomez, Javier
    Cruz Hernandez, Jeddo
    CORSALUD, 2014, 6 (04): : 321 - 333
  • [30] Adding Insult to Injury: Are There Treatments for Myocardial Injury and Type 2 Myocardial Infarction?
    White, Harvey D.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (01): : 1 - 5